{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-052733","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.038493+00:00","generated_at":"2026-05-20T10:21:50.480579+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025","bullets":["Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.","Trial is randomized, double-blind, placebo-controlled; endpoints include safety and lung function (FVC).","Topline data from the REVERT IPF trial is anticipated in the fourth quarter of 2025.","TTI-101 targets STAT3, a central mediator of fibrotic signaling pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-052733","json":"https://secwatch.observer/filing/0001104659-25-052733.json","markdown":"https://secwatch.observer/filing/0001104659-25-052733.md","text":"https://secwatch.observer/filing/0001104659-25-052733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/0001104659-25-052733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/tm2516173d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:21:50.480579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}